$BMEA

Rodman & Renshaw has initiated coverage on Biomea Fusion Inc. (NASDAQ:BMEA) with a Buy rating and a price target of $8.00, suggesting over 500% potential upside. The firm believes Biomea's current valuation disconnects from its clinical progress, highlighting "early clinical validation of a genuine disease-modifying mechanism." This comes as Biomea plans Phase II trials for its diabetes drug, icovamenib, despite a recent downgrade from JPMorgan due to concerns regarding type 2 diabetes data.